Metamizole: EMA wants to reduce the risk of agranulocytosis

Metamizole: EMA wants to reduce the risk of agranulocytosis

0 Comments

Amsterdam – Reports of agranulocytosis have prompted the Pharmacovigilance Committee (PRAC) of the European Medicines Agency (EMA) to update the product information for painkillers containing the active ingredient metamizole. The reason was an application from

EMA examines agranulocytosis risk of metamizole

EMA examines agranulocytosis risk of metamizole

0 Comments

medicine Tuesday, July 30, 2024 Amsterdam The European Medicines Agency (EMA) is reviewing the safety of drugs that contain the painkiller metamizole (Novaminsulfon). There are fears that the existing measures to reduce the risk of